Aspire-Lakewood vs Lexaria Bioscience
ASBP and LEXX side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How ASBP and LEXX compare
Lexaria Bioscience is the larger company, worth 9.3 times as much as Aspire-Lakewood ($110M against $11.8M).
Lexaria Bioscience keeps more of each dollar of sales as profit, with a net margin of −3986% compared with −11314% at Aspire-Lakewood.
Lexaria Bioscience scores higher on the StockData Score (8 against 2 for Aspire-Lakewood), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | ASBP | LEXX |
|---|---|---|
| Size and price | ||
| Market cap | $11.8M | $110M |
| Share price | $8.41 | $4.44 |
| Change, 1 year | 95.9% | −74.0% |
| Change, 5 years | – | −94.7% |
| Beta (5Y) | – | 0.82 |
| Employees | – | 134 |
| StockData Score | ||
| Total score | 2 | 8 (better) |
| Valuation score | 1 (better) | 0 |
| Growth score | 0 | 2 (better) |
| Performance score | 0 | 0 |
| Health score | 1 | 6 (better) |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | 121× (better) | 567× |
| P/B | 1.0× (better) | 23.2× |
| FCF yield | – | −6.8% |
| Growth | ||
| Revenue growth (TTM) | – | −68.5% |
| Revenue growth, 5Y average | – | 17.5% |
| Profitability | ||
| Gross margin | −25.0% | 100% (better) |
| Operating margin | −7495% | −3973% (better) |
| Net margin | −11314% | −3986% (better) |
| FCF margin | – | −3849% |
| Return on equity | −1032% | −150% (better) |
| Return on invested capital | – | −602% |
| Financial health | ||
| Debt / equity | – | 0.00 |
| Interest coverage | −0.8× | – |
| Current ratio | 7.99 | 10.60 (better) |
| Altman Z-score | −0.05 | 126.66 (better) |
| Piotroski F-score | 3 (better) | 2 |
| Dividends and buybacks | ||
| Buyback yield | – | −5.9% |
| Shareholder yield | 0.00% (better) | −5.9% |
| Ownership | ||
| Held by insiders | 1.4% | 3.0% |
| Short interest, % of float | – | 0.90% |
Go deeper
- ASBP stock overview
- ASBP income statement
- ASBP valuation and score
- LEXX stock overview
- LEXX income statement
- LEXX valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.